Future studies could explore the downstream regulatory factors of ZMYM2—such as the transcription factor CEBPB predicted in this study—and investigate whether modulation of the ZMYM2–CEBPB axis can simultaneously improve glucose metabolism in T2D and vascular inflammation in CHD, thereby achieving synergistic therapeutic effects for the comorbidity. This evidence concerns the gene CEBPB and coronary artery disorder.